AQR Capital Management
ATNM icon

AQR Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

AQR Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,805
Closed -$26.9K – 3571
2025
Q3 		$26.9K Sell
16,805
-60,414
-78% -$98.4K ﹤0.01% 3442
2025
Q2 		$108K Buy
77,219
+13,970
+22% +$20.9K ﹤0.01% 3163
2025
Q1 		$102K Buy
63,249
+46,545
+279% +$59.1K ﹤0.01% 3013
2024
Q4 		$21K Sell
16,704
-342,649
-95% -$532K ﹤0.01% 2846
2024
Q3 		$676K Buy
+359,353
New +$1.42M ﹤0.01% 2040

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's ATNM Position: Q4 2025 in Review

AQR Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 16,805 shares — an estimated $26.9K sold.

AQR Capital Management first reported a position in ATNM in Q3 2024 and held it in 5 quarters. The position peaked at $676K in Q3 2024. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.

  • AQR Capital Management reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • AQR Capital Management sold 16,805 Actinium Pharmaceuticals shares in Q4 2025, an estimated $26.9K.
  • AQR Capital Management first reported a position in Actinium Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • AQR Capital Management's Actinium Pharmaceuticals position peaked at $676K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.

Based on AQR Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.